Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• RAS mutations and t(11;14) translocation are common in multiple myeloma (MM), driving uncontrolled cell growth.
• Targeting the RAS/MAPK pathway and cell cycle regulators like cyclin-Ds are potential therapeutic strategies for MM.
• Erk1/2 and CDK4/6 inhibitors have shown efficacy in other advanced cancers.

Purpose of the Study:

• To investigate the anti-MM effects of a combination therapy targeting Erk1/2 and CDK4/6 pathways.
• To evaluate the synergistic cytotoxicity and underlying mechanisms of this combination in MM cells.

Main Methods:

• In vitro testing of Erk1/2 inhibitor (Erk1/2i) plus CDK4/6 inhibitor (CDK4/6i) combination on MM cell lines.
• Assessment of cell cycle arrest, apoptosis induction, and inhibition of key signaling molecules (c-myc, p-RSK, p-S6, p-RB, E2F1).
• Identification of a five-gene signature associated with the combination treatment.

Main Results:

• The Erk1/2i + CDK4/6i combination demonstrated strong synergistic cytotoxicity against MM cells (IC50 < 0.5).
• Treatment induced G0/G1 cell cycle arrest and activated mitochondrial apoptotic pathways.
• Inhibition of key target molecules confirmed on-target activity of the inhibitors.

Conclusions:

• The combination of Erk1/2 and CDK4/6 inhibitors is a potent synergistic treatment for multiple myeloma.
• This combination therapy effectively targets key MM survival pathways and induces apoptosis.
• Results provide a preclinical basis for clinical trials of Erk1/2i + CDK4/6i in MM patients.